Debating the Issues in Rheumatoid Arthritis with the Experts: Early Treatment and Targets

Introduction/Background

RA Is a Heterogeneous Complex Syndrome[a-d]

Different RA Combination Treatments Centered on Single DMARD/Glucocorticoid

RA Treatment Strategies: More Important Than the Agent Selected?

Time to First Remission: Initial Combination vs Initial Monotherapy—DREAM Registry

Or, Sometimes, Is the Agent More Important Than the Strategy Or, Sometimes, Is the Agent More Important Than the Strategy? The RA-BEGIN Trial

Fast-Tracking Patients With High-Risk Early RA

Some Potential Prognostic Factors in RA

Identifying the At-Risk Patients

Biomarker Matrices: SWEFOT Results

Can Biologics Be Tapered or Discontinued?

Initial Combination of Biologic and MTX in Early RA Is Associated With High Levels of DAS28 Remission

Early, Intensive Intervention in Newly Diagnosed Patients: Sustained Remission

Steroids in RA: CAMERA-II Study

Shared Decision-Making and Patient Preferences

Shaping Patient Preferences: Using Imaging to Make RA Real

Many Cytokines and Growth Factors Converge on the JAK Signaling Pathway[a-c]

JAK Inhibitors: Topline Clinical Results[a-c]

Guidelines: Broad Range of Pharmacotherapies Available, But No Clear Selection Criteria

Safety Concerns With bDMARDs in RA

Educational Agenda for Providers of Patient Education: EULAR Recommendations

Potential Toxicities and Overtreatment: Steroids, Results From COBRA-light

Deleterious Effects of Steroids on Mortality in RA

Remote Monitoring of RA Patients With Aggressive Disease

Percentage of Patients With Flare Over Time: Results From the BeSt Study

Summary and Conclusions

Abbreviations

Abbreviations (cont)